Agios Pharmaceuticals (AGIO) concentration risks

Agios Pharmaceuticals' single disclosed concentration is product-driven: the company's ability to generate meaningful revenue depends heavily on the successful development and commercialization of PYRUKYND® and AQVESME™. By disclosed size this is a large exposure with a mixed character — partly structural (the company is organized around a focused rare-disease franchise) and partly dependency (commercial success is uncertain and contingent on adoption, reimbursement, and the absence of competitive or regulatory setbacks). Because the source claim carries no specific revenue percentage or dollar figure beyond the qualitative framing, the share cannot be quantified from the disclosed claim alone. The filing's use of the phrase "generate meaningful revenue" suggests the company remains in a relatively early commercial phase where the product pipeline is the primary value driver rather than a diversified revenue base. The mixed character means two distinct risk vectors are present simultaneously: the structural side reflects a deliberate narrow-focus strategy common in rare-disease companies, where deep expertise in one therapeutic area is a competitive advantage; the dependency side reflects the fact that a clinical or commercial setback for either named product would have a disproportionate impact on the revenue outlook with no currently disclosed offset product generating material revenues. There is no separately disclosed customer, geographic, or supplier concentration in the filing's claims. The profile is therefore straightforward: a single large product concentration where the commercial trajectory of PYRUKYND® and AQVESME™ is the decisive variable for the investment case.

For the engine’s reasoning on AGIO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.